A. D. Beadell Investment Counsel Inc. Boosts Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

A. D. Beadell Investment Counsel Inc. grew its position in Novo Nordisk A/S (NYSE:NVO) by 41.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,012 shares of the company’s stock after purchasing an additional 3,787 shares during the period. A. D. Beadell Investment Counsel Inc.’s holdings in Novo Nordisk A/S were worth $1,119,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S in the 2nd quarter valued at about $25,000. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $28,000. Abound Wealth Management grew its holdings in shares of Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after acquiring an additional 157 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $42,000. Finally, Carolina Wealth Advisors LLC bought a new stake in Novo Nordisk A/S during the third quarter worth $48,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

NVO has been the subject of a number of recent analyst reports. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $0.91 during trading on Friday, hitting $86.55. 2,646,449 shares of the company’s stock traded hands, compared to its average volume of 6,717,778. The stock has a market capitalization of $388.40 billion, a price-to-earnings ratio of 28.01, a PEG ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The business has a 50 day moving average of $100.86 and a 200-day moving average of $119.79. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.